Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases

<p>Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk&#39;s RNAi platform is an ideal approach.</p>